BTIG Research Issues Positive Forecast for Shoulder Innovations (NYSE:SI) Stock Price

Shoulder Innovations (NYSE:SI) had its target price boosted by BTIG Research from $24.00 to $26.00 in a research note issued to investors on Friday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

SI has been the topic of several other reports. UBS Group initiated coverage on Shoulder Innovations in a research report on Tuesday, July 28th. They set a “buy” rating and a $27.00 price target on the stock. Piper Sandler reissued an “overweight” rating and set a $19.00 price objective (up from $18.00) on shares of Shoulder Innovations in a research report on Friday, May 8th. Finally, Weiss Ratings raised shares of Shoulder Innovations from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Shoulder Innovations Price Performance

SI stock opened at $20.54 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 11.81 and a quick ratio of 10.04. Shoulder Innovations has a 1 year low of $10.92 and a 1 year high of $24.59. The firm has a 50-day moving average of $19.91 and a 200 day moving average of $16.07. The company has a market cap of $426.06 million and a P/E ratio of -10.70.

Shoulder Innovations (NYSE:SI) last posted its quarterly earnings data on Wednesday, May 13th. The company reported ($0.41) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.03. Shoulder Innovations had a negative return on equity of 22.93% and a negative net margin of 58.33%.The business had revenue of $16.71 million for the quarter. On average, sell-side analysts forecast that Shoulder Innovations will post -1.67 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Healthcare Holding B.V. Gilde sold 99,812 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The stock was sold at an average price of $22.77, for a total transaction of $2,272,719.24. Following the completion of the transaction, the insider owned 2,221,640 shares of the company’s stock, valued at $50,586,742.80. This trade represents a 4.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Matthew Fraser Ahearn sold 15,856 shares of Shoulder Innovations stock in a transaction on Friday, June 12th. The shares were sold at an average price of $18.68, for a total value of $296,190.08. Following the transaction, the chief operating officer owned 273,320 shares of the company’s stock, valued at $5,105,617.60. The trade was a 5.48% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 188,275 shares of company stock valued at $4,219,793. 29.00% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of SI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Shoulder Innovations in the 3rd quarter worth about $28,000. Rhumbline Advisers purchased a new stake in shares of Shoulder Innovations during the 3rd quarter valued at about $54,000. Wells Fargo & Company MN grew its stake in shares of Shoulder Innovations by 66.3% in the fourth quarter. Wells Fargo & Company MN now owns 5,250 shares of the company’s stock worth $75,000 after acquiring an additional 2,094 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Shoulder Innovations during the fourth quarter valued at approximately $176,000. Finally, Blue Trust Inc. purchased a new position in shares of Shoulder Innovations during the first quarter valued at approximately $228,000.

Shoulder Innovations News Roundup

Here are the key news stories impacting Shoulder Innovations this week:

• Positive Sentiment: Analysts raised their targets: Piper Sandler reaffirmed its “overweight” rating and lifted its price target from $19 to $25, while BTIG Research raised its target from $24 to $26 and initiated a “buy” rating. These targets imply meaningful upside and may support investor sentiment. Benzinga analyst rating updates
• Positive Sentiment: Revenue growth remained strong: Second-quarter revenue increased approximately 56% year over year to $17.2 million, slightly exceeding estimates. Gross profit rose about 60%, indicating continued demand and improving product economics. Shoulder Innovations Q2 2026 earnings summary
• Positive Sentiment: Full-year guidance was raised: SI forecast fiscal-year revenue of $67 million to $69 million, broadly in line with the roughly $67.1 million consensus estimate. Management also highlighted 60% first-half revenue growth. Shoulder Innovations raises full-year outlook
• Neutral Sentiment: Liquidity appears adequate but is declining: The company ended the quarter with $24.5 million in cash and used $7.4 million in operating activities and $2.2 million in capital expenditures. Investors will likely monitor whether revenue growth can lead to improved cash generation.
• Negative Sentiment: Profitability remains a concern: SI reported an operating loss of about $10 million, a net loss of approximately $10.2 million, and diluted EPS near negative $0.49, missing some estimates. The company remains deeply unprofitable, increasing valuation sensitivity. Shoulder Innovations quarterly results
• Negative Sentiment: Major-holder selling may weigh on sentiment: Gilde Healthcare sold more than 110,000 shares in early August for roughly $2.5 million. Although it retains a substantial stake, the sales can raise concerns about near-term supply and insider conviction. Gilde Healthcare insider sale

Shoulder Innovations Company Profile

Shoulder Innovations (NYSE:SI) is a medical device company focused on the design, development and commercialization of shoulder implant systems and related surgical instruments for orthopedic surgery. The company’s product portfolio includes modular shoulder prostheses, humeral and glenoid components, and instrumentation kits designed to facilitate both primary and revision shoulder arthroplasty procedures. Emphasizing a patient-centric approach, Shoulder Innovations works to offer implant solutions that aim to restore mobility and reduce post-operative complications.

In addition to its core implant offerings, Shoulder Innovations provides comprehensive clinical support and training programs for surgeons and operating room teams.